CVM CEL-SCI
- 1.270
- -0.130-9.29%
- 1.370
- +0.100+7.87%
CEL-SCI News
CEL-SCI (CVM.US): The 2024 Q2 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.14 dollars, previous value of -0.19 dollars.
CEL-SCI (CVM.US): The 2024 Q2 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.14 dollars, previous value of -0.19 dollars.
CEL-SCI Q2 2024 GAAP EPS $(0.28) Misses $(0.14) Estimate
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.14) by 100 percent.
Press Release: CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results VIENNA, Va.--(BUSINESS WIRE)--May 16, 2024-- CEL-SCI Corporation (NYSE American: CVM) today reported financial results for th
CEL-SCI 2Q Loss/Shr 14c >CVM
CEL-SCI 2Q Loss/Shr 14c >CVM
CEL-SCI 2Q Loss $7.24M >CVM
CEL-SCI 2Q Loss $7.24M >CVM
CEL-SCI | 10-Q: Quarterly report
CEL-SCI(CVM.US) Director Buys US$27,800 in Common Stock
$CEL-SCI(CVM.US)$ Director Watson Robert Eugene purchased 20,000 shares of common stock on May 8, 2024 at an average price of $1.39 for a total value of $27,800.Source: Announcement What is statement
CEL-SCI(CVM.US) Officer Buys US$11,120 in Common Stock
$CEL-SCI(CVM.US)$ Officer PRICHEP PATRICIA B purchased 8,000 shares of common stock on May 8, 2024 at an average price of $1.39 for a total value of $11,120.Source: Announcement What is statement of
CEL-SCI(CVM.US) Officer Buys US$41,700 in Common Stock
$CEL-SCI(CVM.US)$ Officer KERSTEN GEERT R purchased 30,000 shares of common stock on May 8, 2024 at an average price of $1.39 for a total value of $41,700.Source: Announcement What is statement of cha
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersZai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings
Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine
Cel-Sci (CVM) said Wednesday the US Food and Drug Administration indicated in a recent meeting that the company can move forward with a confirmatory registration study of its investigational cancer tr
Why CEL-SCI (CVM) Shares Are Trading Higher
CEL-SCI Corp (NASDAQ:CVM) shares are trading higher by 18.6% to $1.98 during Wednesday's session after the company received positive feedback from the FDA regarding their cancer immunotherapy, Multiki
CEL-SCI Shares Are Trading Higher After the Company Announced It Received FDA Approval for Its Confirmatory Study of Multikine for the Treatment of Head & Neck Cancer.
CEL-SCI Shares Are Trading Higher After the Company Announced It Received FDA Approval for Its Confirmatory Study of Multikine for the Treatment of Head & Neck Cancer.
CEL-SCI Gains as FDA Greenlights Confirmatory Study for Multikine
CEL-SCI Receives FDA Approval For Its Confirmatory Study Of Multikine For The Treatment Of Head & Neck Cancer
Critical milestone achieved—the FDA accepted CEL-SCI's selection criteria defining the Multikine target population before surgerySelected patient population had 73% survival with Multikine vs. 45% wit
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
Critical milestone achieved—the FDA accepted CEL-SCI's selection criteria defining the Multikine target population before surgery Selected patient population had 73% survival with Multikine vs. 45% without Multikine
Cel-Sci Corp Bolsters Board With Finance Expert Mario Gobbo
CEL-SCI Appoints Mario Gobbo to Its Bd of Directors
CEL-SCI Appoints Mario Gobbo to Its Bd of Directors
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Mario Gobbo to its Board of Directors.
CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
Analysis
Price Target
No Data
